Will Zimulti’s Outlook Be Affected By Suicidality Signal?
This article was originally published in The Pink Sheet Daily
Executive Summary
FDA’s Endocrinologic and Metabolic Drugs Advisory Committee will address psychiatric and neurological profiles of Sanofi-Aventis’ rimonabant for weight management.